Oncolytics Biotech (ONCY) Share-based Compensation (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Share-based Compensation data on file, last reported at $3.0 million in Q3 2025.

• On a quarterly basis, Share-based Compensation rose 817.29% year-over-year to $3.0 million in Q3 2025; TTM through Sep 2025 was $5.1 million, a 351.02% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, changed N/A from the prior year.
• Share-based Compensation for Q3 2025 stood at $3.0 million, up from $377455.6 in the prior quarter.
• Over the last five years, Share-based Compensation for ONCY reached as high as $3.0 million in Q3 2025 and fell as low as -$2.1 million in Q4 2021.
• Historically, Share-based Compensation has averaged $452529.9 across 5 years, with a median of $405935.6 in 2022.
• Across the five-year window, Share-based Compensation sank 543.68% in 2021 and soared 817.29% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at -$2.1 million in 2021, then surged by 125.79% to $551790.5 in 2022, then slumped by 155.15% to -$304339.6 in 2023, then jumped by 381.32% to $856155.6 in 2024, then surged by 249.5% to $3.0 million in 2025.
• Per Business Quant data, the three most recent Share-based Compensation figures were $3.0 million in Q3 2025, $377455.6 in Q2 2025, and $841875.1 in Q1 2025.